Daiichi & AstraZeneca's Datroway Nears EU Approval in Major Cancer Win

TOKYO & LONDON – June 26, 2026 – In a move poised to reshape the frontline treatment for one of the most aggressive forms of breast cancer, the partnership between Daiichi Sankyo and AstraZeneca has secured a critical endorsement in Europe. The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has recommended Datroway for approval, signaling a significant strategic victory and offering a vital new lifeline to a vulnerable patient population.

The positive opinion is for Datroway as a monotherapy for adults with metastatic triple negative breast cancer (TNBC) who are not eligible for immunotherapy. While the European Commission's final sign-off is still pending—a decision typically arriving within two months—the CHMP's backing is the most significant hurdle. This recommendation isn't just another regulatory milestone; it's the culmination of a targeted strategy to replace traditional chemotherapy in a setting where it has long been the only, and often inadequate, option.

A New Standard in a Desperate Fight

Triple negative breast cancer, accounting for about 15% of all breast cancers, is notoriously difficult to treat. It lacks the common hormonal or HER2 protein receptors that newer targeted therapies can latch onto, leaving chemotherapy as the default weapon. For the approximately 70% of metastatic TNBC patients whose tumors don't express PD-L1 or who can't receive immunotherapy for other reasons, the prognosis is grim, with median overall survival hovering between just 12 and 18 months.

This is the challenging landscape that Daiichi Sankyo and AstraZeneca targeted with the TROPION-Breast02 Phase III trial. The results, which underpin the CHMP's decision, are nothing short of practice-changing. The trial demonstrated that Datroway extended median overall survival to 23.7 months, a full 5.0-month improvement over the 18.7 months seen with an investigator's choice of chemotherapy. In the world of oncology, where progress is often measured in weeks, a five-month survival benefit is a monumental achievement.

The data further solidifies Datroway's superiority. It slashed the risk of disease progression or death by 43% and nearly doubled the time patients lived without their cancer worsening—a median progression-free survival of 10.8 months compared to just 5.6 months for chemotherapy. Furthermore, the drug prompted a response in 62.5% of patients, more than double the 29.3% response rate for standard chemotherapy.

"This positive recommendation by the CHMP underscores the potential for Datroway to replace traditional chemotherapy in this setting," said John Tsai, MD, Global Head of R&D, Daiichi Sankyo, highlighting the drug's disruptive potential. Susan Galbraith, Executive Vice President of Oncology R&D at AstraZeneca, echoed this sentiment, noting the dire statistics where only 15% of metastatic TNBC patients survive beyond five years. "This positive opinion... marks an important step forward in bringing the potential of Datroway to transform outcomes for patients," she stated.

The Power of the Platform: ADC Strategy Pays Off

This success is not an isolated event but a powerful validation of Daiichi Sankyo's proprietary DXd antibody-drug conjugate (ADC) platform—the technological engine at the heart of its blockbuster collaboration with AstraZeneca. ADCs are often described as "smart bombs," engineered molecules that combine a monoclonal antibody designed to seek out a specific protein on cancer cells (in this case, TROP2) with a potent chemotherapy payload (DXd). This targeted delivery mechanism aims to maximize cancer-cell killing while minimizing collateral damage to healthy tissue.

The Daiichi Sankyo-AstraZeneca alliance, initiated in 2019 with Enhertu and expanded to include Datroway in 2020, was a multi-billion dollar bet on the dominance of this next-generation ADC technology. Today's recommendation is another major return on that investment. It demonstrates a pattern of execution, building on Datroway's prior EU approval in April 2025 for a different subtype of breast cancer (HR-positive, HER2-negative), which was based on the successful TROPION-Breast01 trial. The ability to secure approvals across different cancer subtypes with the same core technology showcases the platform's versatility and power. For Daiichi Sankyo, which is responsible for manufacturing and supply, it cements its position as a leader in one of oncology's most promising fields.

Navigating the Gauntlet: From Lab to Market

While the science is compelling, the path to market is a strategic gauntlet. With the CHMP's blessing, the final decision from the European Commission is expected by late August or early September 2026. Following that, the real work of securing pricing and reimbursement across 27 different EU member states begins—a complex process that will determine how quickly and widely patients can access the drug.

The competitive landscape is also heating up. Gilead Sciences' Trodelvy, another TROP2-directed ADC, is already an established player in the TNBC space. However, Datroway's robust overall survival data in the first-line setting for an immunotherapy-ineligible population carves out a distinct and highly valuable niche. Rather than simply competing, the Daiichi/AstraZeneca team has strategically positioned Datroway to become the new standard of care for a specific group of patients at the very start of their treatment journey.

This victory is made more significant by the alliance's past hurdles. In late 2024, the partners voluntarily withdrew a European application for Datroway in non-small cell lung cancer (NSCLC) after feedback from the CHMP. That strategic retreat underscores the rigorous nature of the regulatory process and demonstrates that success is never a given. It makes this decisive win in TNBC a testament to the strength of the TROPION-Breast02 data and the team's refined regulatory strategy.

The Bottom Line: Impact on Patients and Portfolios

For patients and their families, the CHMP's recommendation represents tangible hope where little existed. For Daiichi Sankyo and AstraZeneca, it represents the continued, successful monetization of a powerful R&D platform. This approval will not only unlock a significant market in Europe but also strengthen Datroway's commercial standing globally, where it already holds approvals in the U.S. and other key regions for various indications.

The story of Datroway is far from over. With a sprawling clinical development program of more than 20 trials underway, evaluating the drug in lung, urothelial, and other cancers, this TNBC approval is a critical beachhead. It serves as powerful proof of concept for a technology that is fundamentally altering how the industry approaches solid tumors. This isn't just about a single drug's success; it's about how a focused, platform-driven strategy can systematically dismantle the standards of care in oncology, one aggressive cancer at a time.